Â鶹ѧÉú¾«Æ·°æ

Christopher Nevala-Plagemann
( out of 157 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

Sugar House Health Center

Salt Lake City
801-581-2000

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 157 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 23, 2025
    SUGAR HOUSE HEALTH CENTER

    Very understanding. Klowegable. Vary pleasant.

    January 17, 2025
    HUNTSMAN CANCER CENTER

    Excellent and carrying

    January 09, 2025
    SUGAR HOUSE HEALTH CENTER

    Very mindful, attentive, knowledgeable and very pleasant.

    December 26, 2024
    SUGAR HOUSE HEALTH CENTER

    Amazing with communication regarding your conditions and tests. Also, heads & tails above other doctors we have had in the past - amazing with recommendations and process you are making and where he wants to see you get under his care.. Truly a blessing to have him guiding our ship..!!

    December 19, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Was very kind, spending time explaining things we had questions about and explaining our next steps.

    December 11, 2024
    SUGAR HOUSE HEALTH CENTER

    Very straight forward and caring. Perfect for me. Half way through my rounds now.Thank you Dr.Nevala you rock!

    November 22, 2024
    SUGAR HOUSE HEALTH CENTER

    He's a very caring and very understanding person explains things so that you can understand them

    November 21, 2024
    HUNTSMAN CANCER CENTER

    abosolutly the best . respectfull, gets back to you very quickly, honest

    November 14, 2024
    SUGAR HOUSE HEALTH CENTER

    I have been a patient of Dr. Nevala-Plagemann for over a year now. He listens to all of my concerns and is very thorough. I value his opinion. He gives 100% to his patients. [NAME REMOVED]

    See More Patient Comments

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Fellowship Medical Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Network Open, 8(1), e2453588-e2453588.
    2. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
    3. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. ()
    4. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. ()
    5. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. ()
    6. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. ()
    7. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. ()
    8. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. ()
    9. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. ()
    10. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol.
    11. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. ()
    12. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. ()

    Review

    1. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. ()
    2. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. ()
    3. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. ()

    Case Report

    1. Rubnitz Z, Nevala-Plagemann CD, Florou V, Garrido-Laguna I (2025). Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ Case Rep, 18(1), e259660.
    2. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. ()
    3. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. ()
    4. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. ()

    Editorial

    1. Nevala-Plagemann CD, Garrido-Laguna I (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? 21(8), 567-568.

    Abstract

    1. Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States [Abstract]. 31(4), 438.

  • News & Podcasts

    Huntsman Cancer Institute News

  • Clinical Trials